Abstract:Palladium catalysed C-N bond formation in supercritical carbon dioxide has been accomplished. Carbamic acid formation is avoided in part through the use of an N-silylamine as the coupling partner. Employing a catalyst system of Pd2dba3(1 mol%) and 2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl (X-Phos)(2 mol%) enabled the catalytic amination of aryl bromides and chlorides with N-silylanilines to be realised in excellent yield. Extension of the methodology to the N-arylation of N-silyldiarylamines,… Show more
“…[243] Another area of reaction development has been in the application of supercritical carbon dioxide (scCO 2 ) as solvent for the palladium-catalyzed amination of aryl halides using biaryl phosphine ligands (Scheme 71). [244,245] Holmes showed that for successful reaction to occur in this medium it is necessary to protect the amine with a trimethylsilyl group. The authors hypothesize that this is necessary to prevent carbamate formation from occurring.…”
Section: Development Of Reaction Conditionsmentioning
Palladium-catalyzed amination of aryl halides has undergone rapid development in the last 12 years. This has been largely driven by implementation of new classes of ligands. Biaryl phosphines have proven to provide especially active catalysts in this context. This review discusses the applications that these catalysts have found in C-N cross-coupling in heterocycle synthesis, pharmaceuticals, materials science and natural product synthesis.
“…[243] Another area of reaction development has been in the application of supercritical carbon dioxide (scCO 2 ) as solvent for the palladium-catalyzed amination of aryl halides using biaryl phosphine ligands (Scheme 71). [244,245] Holmes showed that for successful reaction to occur in this medium it is necessary to protect the amine with a trimethylsilyl group. The authors hypothesize that this is necessary to prevent carbamate formation from occurring.…”
Section: Development Of Reaction Conditionsmentioning
Palladium-catalyzed amination of aryl halides has undergone rapid development in the last 12 years. This has been largely driven by implementation of new classes of ligands. Biaryl phosphines have proven to provide especially active catalysts in this context. This review discusses the applications that these catalysts have found in C-N cross-coupling in heterocycle synthesis, pharmaceuticals, materials science and natural product synthesis.
“…In path a, the oxidative addition of an aryl halide to Pd 0 species 9 gives ArPdX(Xphos) (10), which generates (ArCOO)PdX(Xphos) (11) in the presence of CO 2 . In path a, the oxidative addition of an aryl halide to Pd 0 species 9 gives ArPdX(Xphos) (10), which generates (ArCOO)PdX(Xphos) (11) in the presence of CO 2 .…”
Section: Direct Carboxylation Of Organic Halides With Comentioning
confidence: 99%
“…[10] In the protocol, the methodology was extended to the N-arylation of N-silyldiarylamines, N-silylazoles, and N-silylsulfonamides. [10] In the protocol, the methodology was extended to the N-arylation of N-silyldiarylamines, N-silylazoles, and N-silylsulfonamides.…”
Although carbon dioxide is an ideal C1 source, its chemical transformations are not widely developed and are still at a rather low level of maturity industrially. In recent years the development of metal‐catalyzed (e.g., Ni, Cu, Rh, Pd, and so on) carboxylation with CO2 as a C1 source has come to represent a potentially powerful method for the preparation of carboxylic acid derivatives. Among these transformations, palladium‐catalyzed carboxylation is one of the most widely investigated. This review presents an overview of recent advances in palladium‐catalyzed carboxylation with carbon dioxide as a C1 carbon source.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.